Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2025-12-25 @ 10:46 PM
Study NCT ID:
NCT01321567
Status:
COMPLETED
Last Update Posted:
2023-07-24
First Post:
2011-03-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Sponsor:
Eisai Co., Ltd.
Organization:
Study Overview
Official Title:
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: